The United Kingdom and the United States have forged a landmark commercial pact that will keep no import taxes on UK medicine exports going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to raise funding on drugs through the National Health Service (NHS). This pledge ensures that tariffs on these vital exports will stay at zero for a duration of the next three years.
This development follows previous warnings to significantly raise import taxes on patented pharmaceutical products, with figures mentioned up to double the cost.
"This arrangement between the United Kingdom strengthens the international landscape for cutting-edge drugs and brings much-needed fairness to transatlantic medicine commerce," an announcement noted.
Commercial Importance
Medicines constitute one of the Britain's biggest goods shipped to the US, which is by far the primary destination for large UK drugmakers.
Trade data reveal that in the year to the end of the third quarter, the UK sold medicines valued at £11.1bn to the US. This value made up nearly one-fifth of total UK exports in that span.
"This deal safeguards work, boosts capital expenditure and paves the way for the UK to emerge as a global hub for medical research," a government official stated.
Specific British Pledges
The agreement entails several specific changes from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise total public funding on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be limited at 15%. In the past, rebates exceeded 20%.
Industry Background
The deal follows a ongoing row between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
These tensions were heightened by claims that American patients were charged significantly more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister stated that the NHS must increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its total funding over the last ten years.
